BRIEF-Cerenome Completes Enrollment In Phase 2 Respect-Gbm Trial Of Reyobiq™ In Recurrent Glioblastoma

4

Oct 29 (Reuters) – Cerenome, Inc: * CERENOME COMPLETES ENROLLMENT IN PHASE 2 RESPECT-GBM TRIAL OF REYOBIQ™ IN RECURRENT GLIOBLASTOMA * CERENOME – EXPECTS TOPLINE PHASE 2 RESPECT-GBM DATA IN MID-2027

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)